Tech Company Financing Transactions
Alentis Therapeutics Funding Round
Alentis Therapeutics, based in Allschwil, secured $181.4 million from Jeito Capital, Novo Holdings and OrbiMed.
Transaction Overview
Company Name
Announced On
11/12/2024
Transaction Type
Venture Equity
Amount
$181,400,000
Round
Series D
Investors
Proceeds Purpose
Alentis will use the money to advance a pipeline of medicines targeting Claudin-1 (CLDN1). Claudin-1 is a protein that plays a role in several diseases, with Alentis chasing treatment for CLDN1-positive tumors and organ fibrosis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Hegenheimermattweg 167A
Allschwil, 4123
CH
Allschwil, 4123
CH
Phone
Undisclosed
Website
Email Address
Overview
Alentis Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough treatments for cancer and fibrotic diseases. Claudin-1 (CLDN1) is a member of the tight junction proteins family. During disease pathogenesis, CLDN1 expression is up-regulated and exposed outside of the tight junction. Exposed, non--tight junctional, CLDN1 drives carcinogenic and fibrogenic signaling in different organs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roberto Iacone
Chief Medical Officer
Luigi Manenti
Chief Operating Officer
Markus Meyer
Chief Technical Officer
Greg Elson
Founder
Thomas Baumert
Browse more venture capital transactions:
Prev: 11/12/2024: Akave venture capital transaction
Next: 11/12/2024: Fleek venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to record all VC transactions involving tech companies. VC investment data records reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs